Get the Stockscreener App
13.05
1.58%
-0.21
After Hours:
13.01
-0.04
-0.31%
Novocure Ltd stock is traded at $13.05, with a volume of 975.90K.
It is down -1.58% in the last 24 hours and down -3.19% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$13.26
Open:
$13.12
24h Volume:
975.90K
Relative Volume:
0.69
Market Cap:
$1.46B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-9.3214
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
+0.27%
1M Performance:
-3.19%
6M Performance:
+8.39%
1Y Performance:
-48.58%
1-Day Range:
$12.91
$13.24
1-Week Range:
$12.91
$14.29
52-Week Range:
$10.70
$26.46
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
13.05 | 1.48B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Emerald Mutual Fund Advisers Trust Has $248,000 Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Short Interest Update - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of “Hold” from Analysts - Defense World
NovoCure’s (NVCR) “Neutral” Rating Reaffirmed at Wedbush - Defense World
Assessing NovoCure: Insights From 4 Financial Analysts - Benzinga
NovoCure (NVCR) Rating Reiterated as Neutral by Wedbush | NVCR S - GuruFocus
A Look At NovoCure (NVCR) Valuation After Record 2025 Revenue And CEO Transition - simplywall.st
NovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbush - MarketBeat
HC Wainwright Has Bullish Estimate for NovoCure Q4 Earnings - MarketBeat
Leerink Partners Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $24 - Futubull
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of "Hold" from Analysts - MarketBeat
Brokers Set Expectations for NovoCure FY2030 Earnings - Defense World
HC Wainwright Comments on NovoCure FY2030 Earnings - MarketBeat
NovoCure (NASDAQ:NVCR) Given New $39.00 Price Target at HC Wainwright - Defense World
Is NovoCure (NVCR) A Rare Opportunity After A 45.9% One Year Share Price Fall - simplywall.st
Why NovoCure Is Failing To Disrupt NSCLC (NASDAQ:NVCR) - Seeking Alpha
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Maintains Buy Rating on NVCR, Lowers Price T - GuruFocus
HC Wainwright Has Lowered Expectations for NovoCure (NASDAQ:NVCR) Stock Price - MarketBeat
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating - Investing.com
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $39 - 富途牛牛
Novocure reports $655 million in preliminary 2025 revenue By Investing.com - Investing.com South Africa
Novocure (NVCR) Surpasses Revenue Expectations with Strong FY25 Performance - GuruFocus
Cancer therapy Novocure hits record sales, awaits 2026 trial results - Stock Titan
Can NovoCure Limited stock double in next 5 years2025 Bull vs Bear & Low Risk High Reward Trade Ideas - Улправда
Will NovoCure Limited stock split attract more investorsProfit Target & Safe Capital Allocation Plans - ulpravda.ru
Can NovoCure Limited stock surprise with earnings upsideEarnings Performance Report & Scalable Portfolio Growth Methods - Улправда
How NovoCure Limited stock reacts to global recession fears2025 Geopolitical Influence & Entry and Exit Point Strategies - ulpravda.ru
How analysts rate NovoCure Limited stock todayMarket Growth Report & Safe Investment Capital Preservation Plans - Улправда
Will NovoCure Limited stock outperform tech sector in 2025Portfolio Growth Summary & Community Verified Watchlist Alerts - Улправда
Total debt per share of NovoCure Ltd. – GETTEX:038 - TradingView — Track All Markets
Voya Investment Management LLC Sells 64,539,786 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025ResearchAndMarkets.com - Bluefield Daily Telegraph
Why NovoCure Limited stock could be next big winnerChart Pattern Recognition & View Live Stock Forecasts Instantly - bollywoodhelpline.com
NovoCure (NVCR): Assessing Valuation After a Recent Rebound From Multi‑Month Lows - Yahoo Finance UK
Has NovoCure’s Tumor Treating Fields Progress Created a Value Opportunity After the 2025 Share Slump? - Yahoo Finance
NovoCure (NVCR): Exploring Valuation After a Recent Share Price Rebound - simplywall.st
Novocure (NVCR) Q2 2025 Earnings Call Transcript - AOL.com
NovoCure (NVCR) Q3 2024 Earnings Call Transcript - The Globe and Mail
First Week of February 2026 Options Trading For NovoCure (NVCR) - Nasdaq
How to hear Novocure’s CEO speak at the J.P. Morgan healthcare event - Stock Titan
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
CapEx per share of NovoCure Ltd. – MUN:038 - TradingView — Track All Markets
Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR) - The Globe and Mail
NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - MSN
Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - simplywall.st
Marshall Wace LLP Sells 392,992 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st
Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):